Lv1
94 积分 2024-08-02 加入
ABL209 (NEOK002) : Designing an EGFRxMUC1 bispecific TOP1i ADC with promising anti-tumor activity and enhanced therapeutic window
2个月前
已完结
In vivo activation of FAP-cleavable small molecule-drug conjugates for the targeted delivery of camptothecins and tubulin poisons to the tumor microenvironment
3个月前
已完结
Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
1年前
已完结
DS-3939a: A TA-MUC1-directed Antibody-Drug Conjugate with Broad Anti-Tumor Activity
1年前
已完结
Preclinical evaluation of DB-1419, a novel bifunctional and bispecific anti-B7-H3×PD-L1 antibody-drug conjugate
1年前
已完结
皖公网安备34019202002308
